<DOC>
	<DOCNO>NCT01041963</DOCNO>
	<brief_summary>A prospective , randomize , open-label , Single-center clinical trial determine whether Enalapril Enalapril plus Losartan effect Peritoneal membrane transportation .</brief_summary>
	<brief_title>The Effect Enalapril Losartan Peritoneal Membrane Continuous Ambulatory Peritoneal Dialysis Patients</brief_title>
	<detailed_description>Detailed description : Many peritoneal dialysis patient suffer uremia due inadequate dialysis volume overload cause failure peritoneal membrane transport.One important etiology peritoneal membrane failure unavoidable use high glucose-containing dialysate solution induce injury mesothelial cell.Previous data find injured mesothelial cell produce Angiotensin ( Ang ) II induce peritoneal inflammation fibrosis . Blockade renin-angiotensin system angiotensin-converting enzyme inhibition ( ACEI ) angiotensin receptor antagonism ( ARB ) play major role slow effect . Although many trial animal study prove benefit ACEI ARB peritoneal membrane transport clinical evidence human controversy . Up , previous trial limitation . First , The trial small number population ( le 20 prospective randomize controlled trial ) . Second , The trial multiple confounders study population study include old case ( peritoneal dialysis many year ) new case ( start treatment le 1 year ) . Third , short duration study ( le 3 month ) see significant effect RAAS blockade peritoneal membrane transport . Forth , study use dialysate albumin loss index peritoneal membrane transport , less sensitivity predict peritoneal membrane function . Fifth , previous trial attempt study effect combination ACEI ARB . Therefore , design study effect ACEI ARB large number population , new case recently find peritoneal dialysis , study take long duration use modify peritoneal equilibrium test dialysate CA125 index peritoneal membrane ( physiology anatomic index ) .This research demonstrate efficacy Enalapril Losartan Peritoneal membrane transportation lead improve quality life CAPD patient .</detailed_description>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>1 . All patient receive CAPD 1 month less 1 year 2 . Subjects either sex , 20 year old 3 . Hypertension 4 . Provision write informed consent subject guardian 1 . No history take ACE inhibitor angiotensinreceptor blocker aldosterone antagonist least 2 month 2 . Serum potassium 5.5 mEq/L 3 . History renal artery stenosis 4 . Peritonitis volume overload within precede 1 month 5 . Myocardial infarction within precede 6 month clinically significant valvular disease active cardiovascular disease 6 . History malignant hypertension hypertensive encephalopathy cerebrovascular accident within precede 6 month 7 . Any condition may preclude patient remain study , alcohol drug abuse , chronic liver disease , malignant disease , psychiatric disorder 8 . History allergy intolerance ACE inhibitor ARB 9 . Hypotension define systolic blood pressure le 90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>ACEI</keyword>
	<keyword>ARB</keyword>
	<keyword>CAPD</keyword>
	<keyword>Peritoneal membrane transport</keyword>
</DOC>